What is Immunetics?
Immunetics operates at the intersection of advanced biotechnology and clinical diagnostics, providing a comprehensive suite of tools essential for modern research and healthcare. The company's portfolio encompasses high-precision antibodies, sophisticated gene editing technologies, and specialized assay kits designed for both academic inquiry and commercial application. By maintaining a global supply chain, Immunetics serves a diverse clientele, including veterinary diagnostic labs and molecular biology research centers. Their market position is defined by a commitment to high-quality reagents that facilitate breakthroughs in immunology, effectively bridging the gap between laboratory discovery and clinical utility.
How much funding has Immunetics raised?
Immunetics has raised a total of $8.1M across 5 funding rounds:
Grant
$2.4M
Grant
$500K
Unspecified
$629K
Grant
$3.7M
Debt
$835K
Grant (2011): $2.4M with participation from National Institutes of Health
Grant (2011): $500K led by The Massachusetts Life Sciences Center
Unspecified (2012): $629K, investors not publicly disclosed
Grant (2012): $3.7M featuring National Institutes of Health
Debt (2014): $835K, investors not publicly disclosed
Key Investors in Immunetics
National Institutes of Health
The National Institutes of Health is the primary agency of the United States government responsible for biomedical and health-related research, providing critical funding to advance scientific discovery.
The Massachusetts Life Sciences Center
The Massachusetts Life Sciences Center is a quasi-public agency that serves as a hub for the global life sciences ecosystem, fostering innovation through strategic investments in science and business.
Undisclosed Investor
Undisclosed investor participating in the funding round, providing essential capital to support the company's ongoing research and development objectives.
What's next for Immunetics?
With the recent infusion of $835K, Immunetics is well-positioned to accelerate its strategic roadmap, focusing on the commercialization of next-generation diagnostic platforms. The company is expected to leverage this capital to enhance its gene editing capabilities and expand its footprint in the veterinary diagnostics market. As the firm transitions into a more mature operational phase, the focus will likely shift toward optimizing its global distribution infrastructure and deepening its integration within the international life sciences ecosystem. This strategic pivot aims to solidify Immunetics' competitive advantage, ensuring sustained growth and continued innovation in the rapidly evolving biomedical landscape.
See full Immunetics company page
